Lipocine (NASDAQ:LPCN) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of Lipocine (NASDAQ:LPCN) from a hold rating to a buy rating in a report published on Friday.

Lipocine Stock Up 1.5 %

Shares of NASDAQ:LPCN opened at $4.84 on Friday. The company has a market capitalization of $25.88 million, a price-to-earnings ratio of -2.83 and a beta of 1.21. The company has a 50 day moving average of $4.58 and a two-hundred day moving average of $5.52. Lipocine has a 52-week low of $2.31 and a 52-week high of $11.79.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The company had revenue of $0.09 million for the quarter. On average, equities analysts anticipate that Lipocine will post -0.92 earnings per share for the current year.

Institutional Investors Weigh In On Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP purchased a new position in Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent quarter. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.